The numbers, as of May 25
- 25 US GLP-1 telehealth programs tracked, prices re-checked every Monday.
- $25/mo the cheapest all-in cash-pay total (Hone Health).
- $179/mo the median all-in cash-pay total across all programs.
- $495/mo the most expensive all-in cash-pay total (Embla).
- 19.8x the price ratio between cheapest and most expensive.
See the full May 2026 Price Index for the per-program breakdown, or pull the change-log JSON feed directly.
What moved this week
Every Monday we re-check all 25 programs against their published pricing. This is the running record of what changed: who raised or cut a price, who added or dropped a lock-in, who restructured, who exited the US. Each entry is dated to the week it was verified.
Price Index, May 2026
The current edition tracks every program by maintenance cash-pay price, by drug. Cheapest all-in is $25/mo (Hone Health); the median is $179/mo; the spread runs 19.8x to the most expensive. Download the source data or embed the live widget.
- CSV every program, every drug, maintenance price, lock-in, score and five sub-scores.
- PDF report editorial summary with methodology and the full chart, ready to send to a source.
- Full landing page the live, sortable chart, refreshed every Monday.
Embed the widget. One iframe, no JavaScript, no tracking cookies. It pulls the latest top-five programs by cash-pay maintenance price and refreshes every Monday.
<iframe src="https://glpchart.com/price-index/embed/" width="100%" height="380" frameborder="0" loading="lazy" title="GLP Chart Price Index, May 2026" style="border: 1px solid #eaeaea; border-radius: 8px; max-width: 720px;"></iframe>Renders in WordPress, Webflow, Ghost, Substack and any CMS that allows raw HTML. For paste-ready quote cards and the journalist FAQ, see the Price Index page.
How we verify
Every price is verified against the program's published pricing page, re-checked weekly. We read the program's own pricing page for the maintenance-dose figure, and when a program's site blocks automated access we confirm the published number through a web search of the program's own materials. Where a program runs a separate cash-pay rail and an insurance-routed rail, we report the cash-pay number. For any number you want to cite, we will send the published source: a link to the program's pricing page or the manufacturer pricing page it came from. Email press@glpchart.com with the specific stat.
For the scoring framework and the five sub-score definitions, see the methodology page. For how we stay independent of the programs we rank, see editorial independence.
A nameable expert, on the record
Topics he can speak to:
- The economics of compounded GLP-1. Why the supply moved off the shortage list, how 503A pharmacies adapted, what the “personalized formulation” trend means in 2026.
- Insurance prior-authorization mechanics. The documented criteria, the appeal pathways, the denial rate by carrier where available.
- Wegovy vs Zepbound. Trial-versus-real-world adherence, dose-response curves, the dropout problem in both registration trials.
- Maintenance dosing and discontinuation. What happens when patients stop, the regain curve, what industry is and is not saying about lifetime use.
- Telehealth program differentiation. Which models work, which are racing to the bottom on price, which are quietly upselling into supplements and coaching.
Request data or a quote
Tell us the stat, table row or claim you want sourced and we will send the underlying file. We reply within one business day, US Central time.
Citation terms
The GLP Chart Price Index and change-log are published under Creative Commons CC BY 4.0. Reuse any number, table row, chart or quote card with attribution and a link back. Suggested citation:
GLP Chart Price Index, May 2026. glpchart.com/price-index. Verified May 25, 2026.
For source-level documentation (links to the published program and manufacturer pricing pages each figure came from), email press@glpchart.com. For embargoed pre-release of next quarter's figures, email at least 72 hours before publication.
